PolyPid (NASDAQ:PYPD) Trading 4.8% Higher

PolyPid Ltd. (NASDAQ:PYPD – Get Rating)’s stock price traded up 4.8% on Wednesday . The company traded as high as $0.39 and last traded at $0.37. 94,833 shares traded hands during trading, a decline of 67% from the average session volume of 288,958 shares. The stock had previously closed at $0.35.

PolyPid Trading Up 4.8 %

The business has a 50-day moving average price of $0.42 and a two-hundred day moving average price of $0.64. The stock has a market capitalization of $7.18 million, a P/E ratio of -0.22 and a beta of 1.25. The company has a current ratio of 2.75, a quick ratio of 2.75 and a debt-to-equity ratio of 0.59.

PolyPid (NASDAQ:PYPD – Get Rating) last released its earnings results on Wednesday, May 10th. The company reported ($0.28) earnings per share for the quarter. On average, analysts expect that PolyPid Ltd. will post -1.05 EPS for the current fiscal year.

Institutional Trading of PolyPid

Several institutional investors and hedge funds have recently modified their holdings of PYPD. Raymond James Financial Services Advisors Inc. lifted its position in shares of PolyPid by 83.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 52,251 shares of the company’s stock worth $285,000 after buying an additional 23,752 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of PolyPid during the 1st quarter worth $72,000. Silverarc Capital Management LLC lifted its position in shares of PolyPid by 1.2% during the 1st quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock worth $1,191,000 after buying an additional 2,555 shares during the last quarter. UBS Group AG lifted its position in shares of PolyPid by 29.9% during the 1st quarter. UBS Group AG now owns 285,399 shares of the company’s stock worth $1,558,000 after buying an additional 65,746 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its position in shares of PolyPid by 514.5% during the 1st quarter. Boothbay Fund Management LLC now owns 122,898 shares of the company’s stock worth $57,000 after buying an additional 102,898 shares during the last quarter. 2.48% of the stock is currently owned by institutional investors.

PolyPid Company Profile

(Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.